These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24922628)

  • 1. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study.
    Lutsey PL; Alonso A; Selvin E; Pankow JS; Michos ED; Agarwal SK; Loehr LR; Eckfeldt JH; Coresh J
    J Am Heart Assoc; 2014 Jun; 3(3):e000936. PubMed ID: 24922628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).
    Ix JH; Katz R; Kestenbaum BR; de Boer IH; Chonchol M; Mukamal KJ; Rifkin D; Siscovick DS; Sarnak MJ; Shlipak MG
    J Am Coll Cardiol; 2012 Jul; 60(3):200-7. PubMed ID: 22703926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis.
    Kestenbaum B; Sachs MC; Hoofnagle AN; Siscovick DS; Ix JH; Robinson-Cohen C; Lima JA; Polak JF; Blondon M; Ruzinski J; Rock D; de Boer IH
    Circ Heart Fail; 2014 May; 7(3):409-17. PubMed ID: 24668259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.
    Ix JH; Shlipak MG; Chertow GM; Whooley MA
    Circulation; 2007 Jan; 115(2):173-9. PubMed ID: 17190862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).
    Mathew JS; Sachs MC; Katz R; Patton KK; Heckbert SR; Hoofnagle AN; Alonso A; Chonchol M; Deo R; Ix JH; Siscovick DS; Kestenbaum B; de Boer IH
    Circulation; 2014 Jul; 130(4):298-307. PubMed ID: 24920722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4.
    Seiler S; Rogacev KS; Roth HJ; Shafein P; Emrich I; Neuhaus S; Floege J; Fliser D; Heine GH
    Clin J Am Soc Nephrol; 2014 Jun; 9(6):1049-58. PubMed ID: 24677555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study.
    Dubin R; Li Y; Ix JH; Shlipak MG; Whooley M; Peralta CA
    Am Heart J; 2012 Feb; 163(2):274-9. PubMed ID: 22305847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA.
    Almahmoud MF; Soliman EZ; Bertoni AG; Kestenbaum B; Katz R; Lima JAC; Ouyang P; Miller PE; Michos ED; Herrington DM
    J Am Heart Assoc; 2018 Sep; 7(18):e008334. PubMed ID: 30371180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Race on the Association of Mineral Metabolism With Heart Failure: the Multi-Ethnic Study of Atherosclerosis.
    Robinson-Cohen C; Shlipak M; Sarnak M; Katz R; Peralta C; Young B; Hoofnagle AN; Szklo M; Ix JH; Psaty BM; de Boer IH; Kestenbaum B; Bansal N
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1144-51. PubMed ID: 31760429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes.
    Waheed S; Matsushita K; Astor BC; Hoogeveen RC; Ballantyne C; Coresh J
    Clin J Am Soc Nephrol; 2013 Mar; 8(3):434-42. PubMed ID: 23258794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor-23 and cardiovascular events in CKD.
    Scialla JJ; Xie H; Rahman M; Anderson AH; Isakova T; Ojo A; Zhang X; Nessel L; Hamano T; Grunwald JE; Raj DS; Yang W; He J; Lash JP; Go AS; Kusek JW; Feldman H; Wolf M;
    J Am Soc Nephrol; 2014 Feb; 25(2):349-60. PubMed ID: 24158986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle-Aged Adults.
    Paul S; Wong M; Akhabue E; Mehta RC; Kramer H; Isakova T; Carnethon MR; Wolf M; Gutiérrez OM
    J Am Heart Assoc; 2021 Aug; 10(16):e020196. PubMed ID: 34387090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study.
    Matsushita K; Williams EK; Mongraw-Chaffin ML; Coresh J; Schmidt MI; Brancati FL; Hoogeveen RC; Ballantyne CM; Young JH
    Am J Epidemiol; 2013 Aug; 178(3):401-9. PubMed ID: 23817916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study.
    Alonso A; Misialek JR; Eckfeldt JH; Selvin E; Coresh J; Chen LY; Soliman EZ; Agarwal SK; Lutsey PL
    J Am Heart Assoc; 2014 Sep; 3(5):e001082. PubMed ID: 25237047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease.
    Tuñón J; Fernández-Fernández B; Carda R; Pello AM; Cristóbal C; Tarín N; Aceña Á; González-Casaus ML; Huelmos A; Alonso J; Lorenzo Ó; González-Parra E; Hernández-González I; Mahíllo-Fernández I; López-Bescós L; Egido J
    Diabetes Metab Res Rev; 2016 Oct; 32(7):685-693. PubMed ID: 26888181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study.
    Deo R; Katz R; de Boer IH; Sotoodehnia N; Kestenbaum B; Mukamal KJ; Chonchol M; Sarnak MJ; Siscovick D; Shlipak MG; Ix JH
    Am J Kidney Dis; 2015 Jul; 66(1):40-6. PubMed ID: 25572028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.
    Astor BC; Shafi T; Hoogeveen RC; Matsushita K; Ballantyne CM; Inker LA; Coresh J
    Am J Kidney Dis; 2012 May; 59(5):653-62. PubMed ID: 22305758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
    Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML
    JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast Growth Factor-23 and Frailty in Elderly Community-Dwelling Individuals: The Cardiovascular Health Study.
    Beben T; Ix JH; Shlipak MG; Sarnak MJ; Fried LF; Hoofnagle AN; Chonchol M; Kestenbaum BR; de Boer IH; Rifkin DE
    J Am Geriatr Soc; 2016 Feb; 64(2):270-6. PubMed ID: 26889836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum parathyroid hormone and 25-hydroxyvitamin D concentrations and risk of incident heart failure: the Multi-Ethnic Study of Atherosclerosis.
    Bansal N; Zelnick L; Robinson-Cohen C; Hoofnagle AN; Ix JH; Lima JA; Shoben AB; Peralta CA; Siscovick DS; Kestenbaum B; de Boer IH
    J Am Heart Assoc; 2014 Dec; 3(6):e001278. PubMed ID: 25468653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.